Janumet

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities increases insulin secretion
increases insulin sensitivity
decreases hepatic glucose production
gptkbp:appointed_by oral tablet
gptkbp:approves gptkb:2007
gptkb:FDA
gptkbp:brand gptkb:Janumet_100/1000
gptkb:Janumet_50/1000
gptkb:Janumet_XR
gptkbp:class antidiabetic agent
biguanide and DPP-4 inhibitor
gptkbp:clinical_trial various studies
glycemic control
gptkbp:contains gptkb:sitagliptin
gptkb:metformin
gptkbp:contraindication gptkb:healthcare_organization
liver disease
hypersensitivity to components
gptkbp:dosage_form gptkb:tablet
100/1000 mg
50/1000 mg
gptkbp:education take with food
report any unusual symptoms
gptkbp:formulation combination therapy
gptkbp:has_ability 100 mg/1000 mg
50 mg sitagliptin and 1000 mg metformin
50 mg/1000 mg
https://www.w3.org/2000/01/rdf-schema#label Janumet
gptkbp:interacts_with gptkb:beer
other diabetes medications
gptkbp:is_available_in gptkb:various_countries
gptkbp:is_monitored_by renal function
liver function
blood glucose levels
gptkbp:is_used_for type 2 diabetes
gptkbp:manufacturer gptkb:Merck_&_Co.
gptkbp:marketed_as various brand names
gptkbp:pharmacokinetics excreted in urine
absorbed in gastrointestinal tract
metabolized in liver
gptkbp:population adults with type 2 diabetes
gptkbp:provides_information_on ADA Standards of Medical Care
AACE Diabetes Management Guidelines
gptkbp:requires gptkb:theorem
gptkbp:safety_features not recommended during breastfeeding
not recommended during pregnancy
monitor for signs of lactic acidosis
gptkbp:shelf_life 2 to 3 years
gptkbp:side_effect nausea
diarrhea
stomach pain
hypoglycemia
vitamin B12 deficiency
pancreatitis
gptkbp:storage room temperature
gptkbp:treatment part of a comprehensive diabetes management plan
gptkbp:type_of_care important for effectiveness
gptkbp:bfsParent gptkb:Dapagliflozin/_Metformin/_Sitagliptin
gptkb:Glucophage
gptkbp:bfsLayer 5